Studies on the Immune Response of Guinea Pigs to the Envelope Substance of <i>Pasteurella Pestis</i>

Walker, Richard V.

doi:10.4049/jimmunol.88.2.153

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Passive protection has been accomplished using antibodies directed against either the F1 or the LcrV antigen [ 37 , 44 , 48 , 49 , 50 , 51 , 52 , 53 , 54 ]. Both mouse- and human-derived anti-F1 mAbs have been demonstrated to protect mice against Y. pestis infection [ 48 , 49 , 55 ]. The anti-LcrV mAb 7.3 antibody is an IgG1 and also protects against plague disease [ 37 , 47 , 56 ].…”

Section: Introductionmentioning

confidence: 99%

Polyclonal Antibodies Derived from Transchromosomic Bovines Vaccinated with the Recombinant F1-V Vaccine Increase Bacterial Opsonization In Vitro and Protect Mice from Pneumonic Plague

Biryukov

Dankmeyer

et al. 2023

Antibodies

View full text Add to dashboard Cite

Plague is an ancient disease that continues to be of concern to both the public health and biodefense research communities. Pneumonic plague is caused by hematogenous spread of Yersinia pestis bacteria from a ruptured bubo to the lungs or by directly inhaling aerosolized bacteria. The fatality rate associated with pneumonic plague is significant unless effective antibiotic therapy is initiated soon after an early and accurate diagnosis is made. As with all bacterial pathogens, drug resistance is a primary concern when developing strategies to combat these Yersinia pestis infections in the future. While there has been significant progress in vaccine development, no FDA-approved vaccine strategy exists; thus, other medical countermeasures are needed. Antibody treatment has been shown to be effective in animal models of plague. We produced fully human polyclonal antibodies in transchromosomic bovines vaccinated with the recombinant F1-V plague vaccine. The resulting human antibodies opsonized Y. pestis bacteria in the presence of RAW264.7 cells and afforded significant protection to BALB/c mice after exposure to aerosolized Y. pestis. These data demonstrate the utility of this technology to produce large quantities of non-immunogenic anti-plague human antibodies to prevent or possibly treat pneumonic plague in human.

show abstract

Section: Introductionmentioning

confidence: 99%

Polyclonal Antibodies Derived from Transchromosomic Bovines Vaccinated with the Recombinant F1-V Vaccine Increase Bacterial Opsonization In Vitro and Protect Mice from Pneumonic Plague

Biryukov

Dankmeyer

et al. 2023

Antibodies

View full text Add to dashboard Cite

show abstract

“…F1–04-A-G1 is an IgG1 mAb that was generated to F1 capsule material and has been demonstrated to protect mice against plague. 33 , 41 The anti-LcrV mAb 7.3 is also an IgG1 subclass antibody and is reliably protective in mouse models of plague. 21 , 39 Due to their excellent passive protection in mice against Y. pestis challenge, anti-F1 F1–04-A-G1 and anti-LcrV 7.3 were used as benchmarks in testing the 21 novel mAbs with unknown protection profiles.…”

Section: Introductionmentioning

confidence: 99%

Functional assays to screen and select monoclonal antibodies that target Yersinia pestis

Biryukov

Rill

Klimko

et al. 2023

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Yersinia pestis is a gram-negative bacterium that causes plague in animals and humans. Depending on the route of disease transmission, the bacterium can cause an acute, often fatal disease that has a narrow window for treatment with antibiotics. Additionally, antibiotic resistant strains have been identified, emphasizing the need for novel treatments. Antibody therapy is an appealing option that can direct the immune system to clear bacterial infections. Advances in biotechnology have made both engineering and producing antibodies easier and more affordable. In this study, two screening assays were optimized to evaluate the ability of antibodies to promote phagocytosis of Y. pestis by macrophages and to induce a cytokine signature in vitro that may be predictive of protection in vivo. We evaluated a panel of 21 mouse monoclonal antibodies targeting either the anti-phagocytic capsule F1 protein or the LcrV antigen, which is part of the type 3 secretion system that facilitates translocation of virulence factors into the host cell, using two functional assays. Anti-F1 and anti-LcrV monoclonal antibodies both increased bacterial uptake by macrophages, with greater uptake observed in the presence of antibodies that were protective in the mouse pneumonic plague model. In addition, the protective anti-F1 and anti-LcrV antibodies produced unique cytokine signatures that were also associated with in vivo protection. These antibody-dependent characteristics from in vitro functional assays will be useful in down-selecting efficacious novel antibodies that can be used for treatment of plague.

show abstract

Cyclic kinetics and mathematical expression of the primary immune response to soluble antigen

et al. 1973

View full text Add to dashboard Cite

Studies on the Immune Response of Guinea Pigs to the Envelope Substance of Pasteurella Pestis

Cited by 5 publications

References 0 publications

Polyclonal Antibodies Derived from Transchromosomic Bovines Vaccinated with the Recombinant F1-V Vaccine Increase Bacterial Opsonization In Vitro and Protect Mice from Pneumonic Plague

Polyclonal Antibodies Derived from Transchromosomic Bovines Vaccinated with the Recombinant F1-V Vaccine Increase Bacterial Opsonization In Vitro and Protect Mice from Pneumonic Plague

Functional assays to screen and select monoclonal antibodies that target Yersinia pestis

Cyclic kinetics and mathematical expression of the primary immune response to soluble antigen

Contact Info

Product

Resources

About